Retatrutide has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA)
3a) showed that the highest sensitivity was obtained when using 200 L AuNPs (10.5 nM)
Compounded semaglutide products are not reviewed or approved by the FDA for safety, effectiveness, or manufacturing consistency, and some formulations may involve different ingredients, concentrations, or semaglutide salts that differ from Novo Nordisks approved medications
Researchers found that patients taking Wegovy were approximately five times more likely to develop ischemic optic neuropathy compared to people using other diabetes medications
However, some may experience mild side effects such as nausea, dizziness, or headaches
Based on these data, the IGF-1 drug itself does not cause oncology, but only has a contraindication to use if you already have cancer or its predisposition (high cancer markers)